(+254) 727688550 or 0736002609

Johnson Ondiek

Johnson Ondiek is a highly experienced Clinical Officer with an extensive background in clinical trials and research. He currently serves at the Kenya Impact Research and Development Organization Clinical Research Site in Kisumu, Kenya, where he brings over 7 years of clinical practice and more than 15 years of clinical research expertise to his role. Prior to this, he held significant positions at the Kenya Medical Research Institute (KEMRI) as a study Coordinator, Field Supervisor and lead Clinician on various clinical trial protocols.Johnson has hands-on experience in clinical trials, particularly focusing on HIV-related trials.

He has actively participated in clinical trials conducted by the Division of AIDS (DAIDS), Aids Clinical Trial Group (ACTG), HIV Prevention Trial Network (HPTN), and Microbicide Trial networks. His dedication to professional growth is evident through his training in various areas related to clinical research, including Good Clinical Practice, Protecting Human Research Participants, Aseptic technique, Clinical Trial Data Management, and Risk Management in Clinical Trials. Johnson’s commitment to continuous learning ensures that he remains current with the latest developments in the field of clinical trials.


  • Diploma in Clinical Medicine and Surgery

Clinical Trials Participated/ study Protocols Executed

  • Solidarity Trial Vaccines: An international randomised trial of candidate vaccines against COVID-19 (STV Study).
  • Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID Study).
  • HVTN703/HPTN 081: A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in sub-Saharan Africa. 2015-2023
  • ACTG 5263: A Randomized Comparison of Three Regimens of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings. 2017-2020.
  • Phase IIa, 90-Day Safety, Adherence, and Acceptability Study of Intravaginal Rings Releasing Tenofovir with and without Levonorgestrel among Women in Western Kenya. (CONRAD Ring study). 2018-2020.
  • A Combination Strategy for HIV Prevention among Female Sex Workers, Nyanza, Kenya (IPrEP Main Study). 22/10/2016 – 31/3/2023
  • IPrEP Men’s Study: Expanding the reach of prevention for men in Kisumu, Kenya (IPrEP Men’s Study). 01/4/2020 – 31/3/2023
  • Simple Amplification Based Assay (SAMBA) Early Infant Diagnosis –Viral Load Study; (2013 to 2015). Multi-Country Validation of SAMBA – A Novel Molecular Point-of- Care Test for HIV-1 Detection in Resource-Limited Setting.
  • HVTN 703/ HPTN 075 study – Feasibility of recruiting and retaining men who have sex with men (MSM) in a multi-country prospective cohort study in preparation for human immunodeficiency virus (HIV) prevention studies in sub-Saharan Africa (SSA). (2015 to 2017)
  • Evaluating Acute and Recent HIV infections longitudinally (EARLY) study (2008 to 2013)
  • Evaluating new incidence of opportunistic infections among those with infections from the HIV/AIDS infection
  • HIV Incidence Cohort Study to Prepare for Future HIV Prevention Clinical Trials in Kisumu, Kenya.
  • HPTN052: A Phase III, Two-arm, Randomized, Controlled, Multi-center Trial to Determine whether Antiretroviral Therapy (ART) can Prevent the Sexual Transmission of HIV-1 in HIV-1 Serodiscordant Couples: 2009-2015


  • Multicounty Validation of SAMBA (Simple Amplified Based Assay) – A Novel Molecular Point-of-Care Test for HIV-1 Detection in Resource-Limited Setting.
  • Evaluation of Syndromic management of sexually transmitted infections within the Kisumu Incidence Cohort Study.